CALL US:022-2204 0015 / 16 / 17   isa@saffronmedia.in
HOME NEWS INGREDIENT MART EVENTS TOPICS INTERVIEW EDIT
 
News
 
Shardul Nautiyal, Mumbai March 30 , 2017
Gujarat Food and Drug Control Administration (FDA) is planning to survey 60 cardiac centres across the state to check price compliance at the point of care.

“The survey which is scheduled to conclude by next week will check whether hospitals and cardiac centres across the state are complying to ceiling price norms stipulated as per the order so that patients are not overcharged,” explains Gujarat FDCA commissioner Dr HG Koshia.

On February 14, 2017, NPPA announced cut in prices of coronary stents by up to 85% by capping them at Rs.7,260 for bare metal ones and Rs.29,600 for drug eluting variety.The step was taken to fix a standardised specification of stent and its MRP to stop fleecing patients.

Since then the official Twitter handle of NPPA has been receiving complaints from hospitals across the country. On February 26, 2017 itself, the official Twitter handle of NPPA tweeted that a complaint was received against Anand Hospital (Meerut), Uttar Pradesh and Mumbai’s KEM Hospital. Prior to this, complaints were received against Bharat Heart Institute (Dehradun), Uttarakhand, Oxygen Hospital (Rohtak), Haryana, Max Hospital Saket, New Delhi, Nidaan Multispecialty Hospital (Sonepat), Haryana and Lilavati Hospital, Mumbai. New Delhi’s Max Hospital and Nidaan Multispecialty Hospital from Haryana.

Post this, NPPA has directed hospitals/nursing homes/clinics utilizing coronary stents shall specifically and separately mention the cost of the coronary stent along with its brand name, name of the manufacturer/importer/batch number. and other details, if any, in their billing to the patients or their representatives.

Non-compliance of these instructions shall be treated as deliberated distortion of evidence along with charges of overpricing. Such cases may also be taken up for prosecution under Essential Commodities (EC) Act, as per NPPA notice.

Maharashtra Food and Drug Administration (FDA) in its verification reports have recently ascertained that no hospital in Mumbai, Pune and Nashik were found violating the ceiling prices for cardiac stents as stipulated by the drug pricing regulator National Pharmaceutical Pricing Authority (NPPA).

The state regulator had stepped up its vigilance as a part of its larger plan to detect overpricing of stents in government and private hospitals subsequent to NPPA receiving complaints about stents being sold at higher prices at KEM Hospital, Lilavati Hospital and a few hospitals in Pune and Nashik.

Share This Story

Leave a Reply
Your name (required)   Your email (required)
         
Website (required)
   
CommenT
 
Enter Code (Required)

 

 

 
INGREDIENT MART

RECENT NEWS

TOPICS
The healthy snacks segment is estimated to be around 2 per cent of the overall snacks market in India, according to expe ...

 

MAIN LINKS OUR SERVICES OTHER PRODUCTS ONLINE MEDIA  
 
About Us
Contact Us
News Archives
 

Product Finder
Features and Articles
News
 
Chronicle Pharmabiz
Food & Bevergae News
Ingredients South Asia
 
Media Information
Rate Card
Advertise
 
 
Copyright © 2013 Saffron Media Pvt Ltd. All Rights Reserved.
Best View in Internet Explorer(9.0) or Firefox(26.0)